Cynthia Madden
About
Cynthia Madden is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine.
According to data from OpenAlex, Cynthia Madden has authored 20 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 8 papers in Dermatology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Cynthia Madden's work include Psoriasis: Treatment and Pathogenesis (11 papers), Autoimmune Bullous Skin Diseases (6 papers) and Dermatology and Skin Diseases (5 papers). Cynthia Madden is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (11 papers), Autoimmune Bullous Skin Diseases (6 papers) and Dermatology and Skin Diseases (5 papers). Cynthia Madden collaborates with scholars based in United States, Canada and United Kingdom. Cynthia Madden's co-authors include Andrew Blauvelt, Christopher L. Cioffi, Veerle Vanvoorden, Kristian Reich, Mark Lebwohl, Richard B. Warren, Richard G. Langley, Kenneth B. Gordon, Dirk De Cuyper and Bruce Strober and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of the Rheumatic Diseases.
In The Last Decade
Cynthia Madden
19 papers receiving 847 citations
Hit Papers
Peers
Cynthia Madden
R. Rivera Spain
R. You Switzerland
Noah Agada United States
Kavitha Goyal United States
R.J.B. Driessen Netherlands
Hasan Tahir United Kingdom
P. M. Houtman Netherlands
Douglas White New Zealand
Klaus Strömer Germany
Tobias Weberschock Germany
Citations per year, relative to Cynthia Madden Cynthia Madden (= 1×)
peers
R. Rivera
Countries citing papers authored by Cynthia Madden
Since
Specialization
Citations
This map shows the geographic impact of Cynthia Madden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cynthia Madden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cynthia Madden more than expected).
Fields of papers citing papers by Cynthia Madden
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Cynthia Madden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cynthia Madden. The network helps show where Cynthia Madden may publish in the future.
Co-authorship network of co-authors of Cynthia Madden
This figure shows the co-authorship network connecting the top 25 collaborators of Cynthia Madden. A scholar is included among the top collaborators of Cynthia Madden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cynthia Madden. Cynthia Madden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sayed, Christopher J., Vivian Y. Shi, Jennifer L. Hsiao, et al.. (2024). Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 8(1). s349–s349.
2.
Kimball, Alexa B., Gregor B. E. Jemec, Christopher J. Sayed, et al.. (2024). Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. The Lancet. 403(10443). 2504–2519.
3.
Gordon, Kenneth B., Richard G. Langley, Richard B. Warren, et al.. (2023). Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. British Journal of Dermatology. 190(4). 477–485.
4.
Thaçi, Diamant, Ronald Vender, Menno A. de Rie, et al.. (2023). Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. British Journal of Dermatology. 188(1). 22–31.
5.
Eyerich, Kilian, Alice B. Gottlieb, Stefano Piaserico, et al.. (2023). 43878 Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial. Journal of the American Academy of Dermatology. 89(3). AB22–AB22.
6.
Kokolakis, Georgios, Richard B. Warren, Bruce Strober, et al.. (2022). Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal of Dermatology. 188(3). 330–340.
7.
Reich, Kristian, Kim Papp, Andrew Blauvelt, et al.. (2021). Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. The Lancet. 397(10273). 487–498.
8.
Gordon, Kenneth B., Peter Foley, James G. Krueger, et al.. (2021). Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet. 397(10273). 475–486.
9.
Reich, Kristian, Richard B. Warren, Mark Lebwohl, et al.. (2021). Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal of Medicine. 385(2). 142–152.
10.
Lebwohl, Mark, Akimichi Morita, Kristian Reich, et al.. (2021). 27376 Speed of clinical response and improvement in psoriasis with bimekizumab: Pooled results from the multicenter, randomized, double-blinded phase 3 BE VIVID, BE READY and BE SURE trials. Journal of the American Academy of Dermatology. 85(3). AB139–AB139.
11.
Strober, Bruce, Kim Papp, Andrew Blauvelt, et al.. (2021). 27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials. Journal of the American Academy of Dermatology. 85(3). AB149–AB149.
12.
Blauvelt, Andrew, Kim Papp, Joseph F. Merola, et al.. (2020). Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. Journal of the American Academy of Dermatology. 83(5). 1367–1374.
13.
Blauvelt, Andrew, Kim Papp, Joseph F. Merola, et al.. (2019). AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY. Annals of the Rheumatic Diseases. 78. 1834–1834.
14.
Madden, Cynthia, et al.. (2006). Sports Medicine and School Nurses: A Growing Need for Further Education and Appropriate Resources. Journal of School Health. 76(1). 8–11.
15.
Madden, Cynthia, Joanne M. Garrett, & Jan Busby‐Whitehead. (1998). The Interface between Nursing Homes and Emergency Departments: A Community Effort to Improve Transfer of Information. Academic Emergency Medicine. 5(11). 1123–1126.
16.
Madden, Cynthia, Joanne M. Garrett, Thomas B. Cole, Jeffrey W Runge, & Carol Q. Porter. (1997). The Urban Epidemiology of Recurrent Injury: Beyond Age, Race, and Gender Stereotypes. Academic Emergency Medicine. 4(8). 772–775.
17.
Madden, Cynthia, Donald B. Witzke, Arthur B. Sanders, John F. Valente, & Mark A. Fritz. (1995). High‐yield Selection Criteria for Cranial Computed Tomography after Acute Trauma. Academic Emergency Medicine. 2(4). 248–253.
18.
Madden, Cynthia. (1995). Elder abuse in the United States. Journal of Clinical Forensic Medicine. 2(1). 1–8.
19.
Madden, Cynthia & Thomas B. Cole. (1995). Emergency Intervention to Break the Cycle of Drunken Driving and Recurrent Injury. Annals of Emergency Medicine. 26(2). 177–179.
20.
Madden, Cynthia. (1992). A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. Annals of Emergency Medicine. 21(8). 1014–1014.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by R. Rivera Breakdown of academic impact, for papers by R. You Breakdown of academic impact, for papers by Noah Agada Breakdown of academic impact, for papers by Kavitha Goyal Breakdown of academic impact, for papers by R.J.B. Driessen Breakdown of academic impact, for papers by Hasan Tahir Breakdown of academic impact, for papers by P. M. Houtman Breakdown of academic impact, for papers by Douglas White Breakdown of academic impact, for papers by Klaus Strömer Breakdown of academic impact, for papers by Tobias Weberschock